Pharmacogenomics Corner

Back to articles

Genetic testing helps predict cardiac risk, statin benefits

KEY POINT

Use of a genetic risk score based on 27 genetic single nucleotide polymorphisms (SNPs) in more than 48,000 primary and secondary prevention patients helped determine who was at increased risk for cardiovascular events and who would benefit the most from statin therapy, according to new data published in Lancet.